CRISPR/Cas9-mediated noncoding RNA editing in human cancers.

CRISPR/Cas9-mediated noncoding RNA editing in human cancers.

RNA Biol. 2017 Oct 13;:0

Authors: Yang J, Meng X, Pan J, Jiang N, Zhou C, Wu Z, Gong Z

Abstract
Cancer is characterized by multiple genetic and epigenetic alterations, including a higher prevalence of mutations of oncogenes and/or tumor suppressors. Mounting evidences have shown that noncoding RNAs (ncRNAs) are involved in the epigenetic regulation of cancer genes and their associated pathways. The clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease 9 (CRISPR/Cas9) system, a revolutionary genome-editing technology, has shed light on ncRNA-based cancer therapy. Here, we briefly introduce the classifications and mechanisms of CRISPR/Cas9 system. Importantly, we mainly focused on the applications of CRISPR/Cas9 system as a molecular tool for ncRNA (microRNA, long noncoding RNA and circular RNA, etc.) editing in human cancers, and the novel techniques that are based on CRISPR/Cas9 system. Additionally, the off-target effects and the corresponding solutions as well as the challenges toward CRISPR/Cas9 were also evaluated and discussed. Long- and short-ncRNAs have been employed as targets in precision oncology, CRISPR/Cas9-mediated ncRNA editing may provide an excellent way to cure cancer.

PMID: 29028415 [PubMed - as supplied by publisher]

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ynriXW
via IFTTT